Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.255 USD | +5.91% | +35.70% | -61.18% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.18% | 75.43M | |
+4.42% | 111B | |
+10.95% | 105B | |
-12.01% | 22.34B | |
-3.81% | 21.93B | |
-5.94% | 18.59B | |
-36.52% | 18.12B | |
-10.04% | 16.96B | |
+3.07% | 13.7B | |
+37.10% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio : Maxim Adjusts Annovis Bio's PT to $45 from $12, Keeps Buy Rating